For academic research
Turn scientific discovery into real-world impact
Promising research stalls when access to the right tools isn’t there. Vipergen bridges the gap — giving academic labs access to state-of-the-art DEL screening technology without the infrastructure, protein prep, or budget barriers.
The academic reality
Built for cutting-edge research
Academic labs are often first to discover novel biology. Traditional screening methods shouldn’t be what holds that science back.
Novel biology and first-in-class targets
Academic groups are often working at the frontier of target biology. Our in-cell platform is purpose-built for exactly this kind of unexplored science.
No purified protein required
Complex protein purification workflows are a common bottleneck. Our cBTE technology screens directly in living cells — bypassing that barrier entirely.
Limited budgets and infrastructure
Building advanced screening capabilities in-house isn’t feasible for most academic institutions. We provide access without the overhead.
Unexplored mechanisms of action
Early-stage hypothesis validation requires tools that can keep pace with the science. Our platform supports exploratory research without artificial constraints.
“Promising ideas can stall before they ever reach their full potential. We help bridge that gap.”
500M+
drug-like compounds screened per experiment
In-cell
screening in physiologically relevant conditions from day one
How it works
From hypothesis to validated discovery
A collaborative process built around your research goals — whether publication, target validation, or translational development.
01
Define the research question
We align on your target, biological context, and goals — whether fundamental research, target validation, or early translational work. No purified protein required.
02
In-cell DEL screening
Hundreds of millions of compounds screened directly inside living cells using our proprietary cBTE technology — generating biologically relevant data from the start.
03
Actionable data delivered
Ranked hits with structural information gives you data that supports publications, strengthens grant applications, and opens the door to translational follow-up.
Our platform
Explore biology in its native environment
Three proprietary DEL technologies that let you investigate targets and mechanisms that conventional screening methods can’t access.
Library synthesis
YoctoReactor® (yR)
Creates vast small-molecule DELs with a perfect match between DNA barcodes and displayed compounds — the foundation for high-fidelity screening. Enables ultra-high screening capacity in a single experiment.
In vitro screening
Binder Trap Enrichment® (BTE)
A homogeneous in vitro screening technology for rapid, comprehensive DEL screening. Ideal for targets where purified protein is available and in vitro conditions are appropriate.
In-cell screening
Cellular BTE® (cBTE)
The world’s only technology for screening DELs inside a living cell. No purified protein needed. More physiologically relevant results from day one — expanding the target space to previously “undruggable” biology.
Academic collaboration model
Designed around how academia works
We work closely with universities and research institutions to create collaboration frameworks that support both scientific and institutional goals.
Publication and data sharing flexibility
Your science, your story. We structure collaborations with clear terms around publication rights and data sharing from the outset.
Aligned with technology transfer processes
We understand institutional requirements. Our collaboration structures are designed to be compatible with university IP and tech transfer frameworks.
Translational research support
For research with therapeutic potential, we can help bridge the path from early academic discovery toward drug development and industry partnership.
Scientific alignment throughout
Dedicated scientific support at every stage. We are a collaborative partner, not just a service provider — invested in the outcome of your research.
Platform credentials
Research-grade rigor at industrial scale
The same platform trusted by top-5 pharma companies globally — now accessible to academic research groups through flexible collaboration models.
500M+
Drug-like molecules screened per experiment via the YoctoReactor® platform — providing coverage of chemical space no academic library can match.
90+
Partnerships with pharma and biotech companies worldwide — bringing proven, validated technology into every academic collaboration we undertake.
#1
The first and only platform screening DELs inside living cells — enabling biological insights no in vitro approach can replicate.
When to work with us
The right partner when your science needs to go further
Whether you’re validating a new target, pursuing a grant, or exploring a path toward translation — Vipergen gives you the tools to go further.
Novel target validation
Generate hit data against a new target early — without building an assay platform or producing purified protein. Validate your biology before committing resources.
Exploring new mechanisms of action
Screen across vast chemical space to discover unexpected binding modes, allosteric sites, or novel chemotypes relevant to your research question.
Strengthening publications and grants
High-quality hit data with structural information makes publications stronger and grant applications more compelling. Move from hypothesis to supporting evidence faster.
Hard-to-drug or membrane targets
GPCRs, ion channels, PPIs — targets that conventional methods struggle with are precisely where in-cell screening opens new doors for academic discovery.
Bridging academia and industry
For research with translational potential, our data and collaboration framework can serve as the foundation for licensing discussions or industry partnerships.
Early-stage drug discovery projects
Academic groups pursuing early drug discovery programs gain access to industrial-grade screening capability — without needing industrial resources to match.